Volume : 09, Issue : 12, December – 2022
Title:
55.INVESTIGATING THE HYPOTENSIVE EFFECTS OF INTRAVENOUS STREPTOKINASE AMONG PATIENTS WITH MYOCARDIAL INFARCTION AT GANGARAM HOSPITAL LAHORE
Authors :
Ms: Nighat Firdaus, Ms:Ayesha Ramzan , Ms:Shazia Eshaq
Abstract :
Background/ Objective: A fall in blood pressure frequently occurs during the infusion of streptokinase in patients with myocardial infarction. Thus, hypotension is a common among the several adverse drug reactions induced by streptokinase infusion. However, there is paucity of evidences locally available to prevent and manage these reactions. The present study investigates the hypotensive effects alongside the other adverse drug reactions during streptokinase infusion in patients with myocardial infarction.
Design and subjects: This study has been conducted among the patients with MI visiting cardiac emergency of Sir Ganga Ram Hospital (SGRH), Lahore. The data have been collected retrieved from N=60 patients who were given streptokinase for thrombolytic therapy. Systolic blood pressure measurements and corresponding intervals during the occurrence of this reaction have obtained and observed.
Results: Hypotension was reported as the most common adverse drug reaction that occurred among (n=31%) followed by hemorrhagic stroke (30%), recurrent chest pain (25%), bleeding (13%), and coughing (13%). Streptokinase induced hypotension occurred at a median of 15(13) minutes after starting streptokinase infusion. Hypotensive episode recovered in a median duration of 15(10) minutes with appropriate interventions. Apart from temporarily withholding streptokinase, most patients required a combination of fluid therapy and vasopressor support to restore systolic blood pressure.
Conclusion: The risk and benefit of administering streptokinase must be assessed and effective strategies can be implemented to ensure whether streptokinase treatment is safe to all myocardial infarction patients. Moreover, the early intravenous administration of streptokinase in the hospital setting leads to a reduced rate of major cardiovascular events compared to delayed administration. However, mortality rates were not significantly affected. Secondary prevention should be targeted on modifiable demographic and psychosocial risk factors of myocardial infarction.
Keywords: Streptokinase, Myocardial Infarction, Hypotension.
Cite This Article:
Please cite this article in press Nighat Firdaus et al, Investigating The Hypotensive Effects Of Intravenous Streptokinase Among Patients With Myocardial Infarction At Gangaram Hospital Lahore.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Psychosocial risk factors of myocardial infarction and adverse effects of streptokinase in public sector hospitals. Pak J Med Sci, 31, 821-6.
3. ALBUS, C. 2010. Psychological and social factors in coronary heart disease. Ann Med, 42, 487-94.
4. ASLANABADI, N., SAFAIE, N., TALEBI, F., DOUSTI, S. & ENTEZARI-
5. MALEKI, T. 2018. The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction. Iran J Pharm Res, 17, 53-63.
6. BABAR, M. Z. M., MAJID, A. & IQBAL, J. 2016. Acute myocardial infarction; effects of thrombolysis on TIMI flow rate in infarct related artery (IRA) in patients of ST elevated acute myocardial infarction. Prof Med J, 23, 1412- 1416.
7. BETANCOURT, B. Y., MARRERO-MIRAGAYA, M. A., JIMÉNEZ-LÓPEZ, G., VALENZUELA-SILVA, C., GARCÍA-IGLESIAS, E., HERNÁNDEZ- BERNAL, F., DEBESA-GARCÍA, F., GONZÁLEZ-LÓPEZ, T., ALVAREZ-
8. FALCÓN, L. & LÓPEZ-SAURA, P. A. 2005. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol, 5, 5.
9. BUCKLEY, T., MCKINLEY, S., GALLAGHER, R., DRACUP, K., MOSER, D. K.
10. & AITKEN, L. M. 2007. The Effect of Education and Counselling on Knowledge, Attitudes and Beliefs about Responses to Acute Myocardial Infarction Symptoms. Eur J Cardiovasc Nurs, 6, 105-111.
11. BUNKER, S. J., COLQUHOUN, D. M., ESLER, M. D., HICKIE, I. B., HUNT, D.,
12. JELINEK, V. M., OLDENBURG, B. F., PEACH, H. G., RUTH, D.,
13. TENNANT, C. C. & TONKIN, A. M. 2003. “Stress” and coronary heart disease: psychosocial risk factors. Med J Aust, 178, 272-6.
14. CAPITANESCU, C., MACOVEI OPRESCU, A. M., IONITA, D., DINCA, G. V., TURCULET, C., MANOLE, G. & MACOVEI, R. A. 2016. Molecular processes in the streptokinase thrombolytic therapy. J Enzyme Inhib Med Chem, 31, 1411-1414.
15. CHAU, H. & CHOI, K. 2013. Efficacy and Safety of Tenectaplase versus Streptokinase in Treating ST-Elevation Myocardial Infarction Patients in Hong Kong: A Four-Year Retrospective Review in Queen Elizabeth Hospital. Hong Kong J Emerg Med, 20, 359-363.
16. DEVI, P., KAMATH, D. Y., ANTHONY, N., SANTOSH, S. & DIAS, B. 2012.
17. Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital. Eur J Clin Pharmacol, 68, 427- 33.
18. EDWARDS, I. R. & ARONSON, J. K. 2000. Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 356, 1255-1259.
19. EK, A., EKBLOM, Ö., HAMBRAEUS, K., CIDER, Å., KALLINGS, L. V. &
20. BÖRJESSON, M. 2019. Physical inactivity and smoking after myocardial infarction as predictors for readmission and survival: results from the SWEDEHEART-registry. Clin Res Cardiol, 108, 324-332.
21. ELSAYED, Y. M. H. 2020. Streptokinase-inducing hypotension in acute myocardial infarction but blood pressure normalizing in acute massive pulmonary embolism; Why? Thromb Haemost Res 4, 1046.
22. GEMMILL, J. D., HOGG, K. J., DOUGLAS, J. T., DUNN, F. G., LOWE, G. D. O.,
23. RAE, A. P. & HILLIS, W. S. 1993. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardixal infarction with streptokinase-containing agents — lack of relationship to pretreatment streptokinase resistance. Eur Heart J, 14, 819-825.
24. HAMID, S., KUNDAL, V., MAHAJAN, N. & SINGH, P. 2015. Failure of
25. thrombolysis with streptokinase in acute myocardial infarction using ECG criteria: An observational study. JK Science, 17, 123.
26. HERLITZ, J., HARTFORD, M., AUNE, S. & KARLSSON, T. 1993. Occurrence of
27. hypotension during streptokinase infusion in suspected acute myocardial infarction, and its relation to prognosis and metoprolol therapy. Am J Cardiol, 71, 1021-1024.
28. KASIM, K. 2012. Basic concepts of modern epidemiology: Epidemiology and research, Saarbrucken, Germany, LAP LAMBERT Academic Publishing
29. KHALID, K., AHMAD, R., LUI, S. & ABIDIN, I. 2021a. Killip classification and baseline heart rate can be used to predict streptokinase‑induced hypotension in acute myocardial infarction. World Acad Sci J, 3(4), 1-7.
30. KHALID, K., ELINA AHMAD, R., Y.H. TONG, A., YEE LUI, S. & ZAINOL
31. ABIDIN, I. Z. 2021b. Pathophysiology of streptokinase-induced hypotension in acute myocardial infarction: a systematic review of clinical evidence. Arch Med Sci Atheroscler Dis, 6, 85-94.
32. KO, A. T. Y., TEO, Y., TEO, H. G. & CHAM, Y. L. 2019. Factors and outcomes associated with streptokinase-related hypotension in patients with ST Segment Elevation Myocardial Infarction (STEMI) in A secondary care hospital in Malaysia. Int J Cardiol, 297, 16-17.
33. LATEEF, F. & ANANTHARAMAN, V. 2000. Hypotension in acute myocardial infarction patients given streptokinase. Singapore medical journal, 41, 172- 176.
34. LEW, A. & GANZ, W. 1986. Streptokinase thrombolytic therapy in acute myocardial infarction. Pathophysiol Haemos Thromb, 16, 113-121.
35. LEW, A., LARAMEE, P., CERCEK, B., SHAH, P. & GANZ, W. 1985. The
36. hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation, 72, 1321-1326.
37. MAGGIONI, A. P., FRANZOSI, M. G., SANTORO, E., WHITE, H., VAN DE
38. WERF, F. & TOGNONI, G. 1992. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico II (GISSI- 2), and The International Study Group. N Engl J Med, 327, 1-6.
39. MOHEBBI, N., SHALVIRI, G., SALARIFAR, M., SALAMZADEH, J. &
40. GHOLAMI, K. 2010. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf, 19, 889-94.
41. PAVKOVIĆ, B. & KLAČAR, M. 2018. Acute myocardial infarction in a patient with coronary artery aneurysm. Timočki medicinski glasnik, 43(4),183-187.
42. PERNAT, A., POHAR, B. & HORVAT, M. 1997. Effect of hydrocortisone on streptokinase-induced hypotension in patients with acute myocardial infarction. Fibrinolysis and Proteolysis, 11, 103-107.
43. REDZUAN, A. M., MOHAN, K. & NAGARAJAH, J. 2021. Risk factors associated with the occurrence of streptokinase induced hypotension among ST-elevation myocardial patients (STEMI). J Cardiovasc Dis Res, 12, 1301-1309.
44. SANTUCCI, A., RICCINI, C. & CAVALLINI, C. 2020. Treatment of stable
45. ischaemic heart disease: the old and the new. Eur Heart J Suppl, 22, E54-e59.
46. SAWAR, S., KHAN, B., KHAN, A. T., NOOR, N., RAHMAN, F. & REHMAN, N.
47. 2019. Complications of streptokinase in patients with acute st segment elevation myocardial infarction: No reason to withhold this effective therapy. JPMI: J Postgrad Med Insti, 33(4), 293-298.
48. SHIFERAW, M. B., SINISHAW, M. A., AMARE, D., ALEM, G., ASEFA, D. &
49. KLINKENBERG, E. 2021. Prevalence of active tuberculosis disease among healthcare workers and support staff in healthcare settings of the Amhara region, Ethiopia. PLOS ONE, 16, e0253177.
50. SULTANA, R., SULTANA, N., RASHEED, A., RASHEED, Z., AHMED, M.,
51. ISHAQ, M. & SAMAD, A. 2010. Door to needle time of streptokinase and ST segment resolution assessing the efficacy of reperfusion therapy at Karachi Institute of Heart Diseases. J Ayub Med Coll, 22(1), 150-3.
52. SYMONS, R., MASCI, P. G., FRANCONE, M., CLAUS, P., BARISON, A., CARBONE, I., AGATI, L., GALEA, N., JANSSENS, S. & BOGAERT, J.
53. 2016. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker’s paradox revisited. Europ Heart J, 37, 2756-2764.
54. TATU-CHIŢOIU, G., TEODORESCU, C., DAN, M., GURAN, M., CĂPRARU, P., ISTRĂŢESCU, O., TATU-CHIŢOIU, A., BUMBU, A., CHIONCEL, V.,
55. ARVANITOPOL, S. & DOROBANŢU, M. 2004. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA). Rom J Intern Med, 42, 557-73.
56. WANG, X. & KATTAN, M. W. 2020. Cohort Studies. Chest, 158, S72-S78.
57. WHO. 2022. Cardiovascular diseases (CVDs): Key facts [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases- (cvds) [Accessed 10 Semptember 2022].
58. YU, S.-H., LI, L. & ZHANG, S. 2016. Clinical effect of intravenous thrombolysis combined with nicorandil therapy in patients with acute ST-segment elevation myocardial infarction. Trop J Pharm Res, 15, 1335-1339.
59. YUSOF, T. T., LIU, K. & KASIM, S. 2019. Impact of a regional STEMI network on patient outcomes in Malaysia. Int J Cardiol, 297, 16-30.
60. ZIA, M. A. 2020. Streptokinase: an efficient enzyme in cardiac medicine. Protein Pept Lett, 27, 111-119.